A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs CX 8998 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Proof of concept
- Acronyms T-WAVE
- Sponsors Cavion
- 19 Nov 2018 Planned End Date changed from 25 Nov 2018 to 25 Mar 2019.
- 19 Nov 2018 Planned primary completion date changed from 25 Nov 2018 to 25 Jan 2019.
- 26 Jul 2018 Parallel assignment has been changed to single group assignment. Now study is open labelled, previously it was double blind. Treatment arms and planned patient number has been reduced.